Status:
COMPLETED
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Celgene Corporation
Alberta Cancer Foundation
Conditions:
T-cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
T-cell Non-Hodgkin's lymphomas are a group of cancers that are usually treated with chemotherapy, radiation therapy, or occasionally surgery. T-cell lymphomas are relatively uncommon and therefore not...
Detailed Description
Background: T-cell lymphomas comprise 10-15% of all non-Hodgkin's lymphomas and include a variety of histological subtypes. These diseases have variable clinical behaviour, response to therapy, and lo...
Eligibility Criteria
Inclusion
- T-cell lymphoma (excluding mycosis fungoides)
- WHO performance status 0-2
- measurable lesions
- acceptable hematological and biochemical parameters
- previously treated OR untreated but not suitable for standard therapy
Exclusion
- pregnant
- HIV
- viral hepatitis
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00322985
Start Date
June 1 2006
End Date
July 1 2014
Last Update
March 16 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Tom Baker Cancer Centre
Calgary, Alberta, Canada
2
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
3
Cancer Care Manitoba
Winnipeg, Manitoba, Canada
4
Queen Elizabeth II, Health Services Centre
Halifax, Nova Scotia, Canada